An IBD Medication Appeal Letter Template and Documentation Checklist

When an insurer denies a biologic or small molecule drug for Crohn's disease or ulcerative colitis, the appeal letter is the document that does the persuading. Everything else in the packet is evidence; the letter is the argument tying that evidence to the plan's coverage rules. Delays carry measurable clinical cost. A study of prior authorization in inflammatory bowel disease found that authorizations requiring appeals or peer review added roughly 25 days to treatment initiation and were associated with a 14.1% increased likelihood of corticosteroid dependence at 90 days. A review of 220 patients found that median insurance approval time rose from 7 days to 29 days when an appeal was required, with longer approval times associated with worse C-reactive protein improvement.

What the letter has to prove

An appeal letter answers a specific question: does this drug, for this patient, meet the plan's definition of medical necessity? The letter has to connect three things. First, the denial reason itself, which the plan is required to state specifically. Federal claims rules require the denial notice to set out the specific reason for the adverse determination and reference the specific plan provisions on which it is based, along with the internal rule or clinical guideline used, or a statement that the rule will be provided free of charge. Second, the patient's documented disease history and prior therapy. Third, the label and guideline language that makes this drug the appropriate next step. A letter that addresses only the third element reads as advocacy. A letter that addresses all three reads as a coverage argument.

A letter template you can adapt

The template below is meant to be filled in by the patient and reviewed by the prescribing office. Each bracketed field corresponds to a document in the checklist below, so the letter and the packet get built together.

Re: Appeal of denial dated [date] | Member [name] | Member ID [number] | Claim/Reference [number] | Drug [name and dose]

I am appealing the denial of [drug name] issued on [date]. The denial letter states the reason as [quote the plan's exact stated reason]. I am requesting reconsideration under the plan's medical necessity criteria, and I am enclosing clinical documentation in support.

Diagnosis and disease course. I was diagnosed with [Crohn's disease / ulcerative colitis], [location and extent], in [year]. My current disease activity is documented by [endoscopy date and findings], [imaging date and findings], and [lab values, including CRP and fecal calprotectin with dates].

Prior therapies and outcomes. I have been treated with [drug], [dates], at [dose], with the outcome [no response / loss of response / intolerance, with the specific adverse effect and date]. [Repeat for each prior agent.] Drug level and antibody testing on [date] showed [result].

Why this drug is appropriate now. [Drug name] is indicated for my condition and disease severity, and my treating gastroenterologist has determined it is the appropriate next therapy because [reason tied to the failure pattern above].

Request. I ask that the plan approve coverage of [drug, dose, frequency]. If the denial is upheld, please provide the internal rule, guideline, or clinical criterion relied upon and the credentials of the reviewer.

Sincerely, [name, date, contact information]

The quoted denial reason matters more than it looks. Answering the plan's stated ground directly, in its own words, prevents the reviewer from upholding the denial on a point the letter never addressed.

The clinical evidence that carries weight

Two categories of evidence do most of the work. The first is the drug's labeled indication. The infliximab label, for example, covers inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and risankizumab carries approved indications in Crohn's disease and ulcerative colitis. Quoting the indication and matching it to documented severity closes the on-label question.

The second is guideline positioning. The 2025 American College of Gastroenterology guideline for Crohn's disease in adults recommends against a strict step-up approach and supports early advanced therapy in appropriate moderate-to-severe cases, with risankizumab preferred over ustekinumab in patients previously exposed to anti-TNF agents. That language is directly useful when a denial rests on a fail-first requirement. Where the denial follows loss of response, note that the annual risk of losing response to anti-TNF therapy in Crohn's disease is roughly 20.9% per patient-year, and that drug trough levels and antidrug antibody results distinguish mechanistic failure from underdosing. Both the NIDDK Crohn's treatment overview and its ulcerative colitis counterpart note that corticosteroids are not intended for long-term use, which supports urgency when steroids are the only thing holding a flare.

The documentation checklist

Assemble these with the prescribing office before the letter goes out. Federal rules entitle a claimant to reasonable access to and copies of all documents, records, and other information relevant to the claim, free of charge, so anything the plan used against you can be requested.

• Clinical record: office notes, endoscopy and pathology reports, imaging, and dated CRP and fecal calprotectin values showing active inflammation
• Therapy history: every prior agent with start and stop dates, doses, dose escalations, outcomes, adverse effects, and any drug level or antibody testing
• Plan documents: the denial letter, the summary plan description, the formulary listing, and the internal criterion the plan relied on

A letter of medical necessity signed by the gastroenterologist should accompany the patient letter rather than replace it, since the two carry different weight with different reviewers.

Timing and delivery details that protect the letter

Under ERISA claims rules, plans must allow at least 180 days after receipt of an adverse benefit determination to appeal and must let claimants submit written comments, documents, and records. For urgent claims, the plan must decide no later than 72 hours after receipt, with the treating provider's judgment of urgency binding on the plan; the same rule requires continued coverage pending appeal and requires the plan to share any new evidence or rationale in advance of a final denial. When the issue is formulary placement rather than medical necessity, the exceptions pathway is faster: plans must decide standard exception requests within 72 hours and expedited requests within 24 hours. Send the packet by a method that produces a delivery record and note the case reference number on every page.

A denial letter is the plan stating its reasoning in writing, which is the one moment when the disagreement becomes specific enough to answer point by point. The letter that succeeds is usually the one that quotes the denial, matches each stated deficiency to a dated document, and asks for the criterion in writing if the answer is still no.